Cambridge Cognition Holdings PLC Result of AGM & Change of Name of NOMAD & Broker
28 Juni 2024 - 2:48PM
RNS Regulatory News
RNS Number : 4101U
Cambridge Cognition Holdings PLC
28 June 2024
28 June 2024
Cambridge Cognition Holdings
plc
("Cambridge Cognition", the "Company" or the
"Group")
Result of AGM
Change of Name of Nominated
Adviser and Joint Broker
Cambridge Cognition
plc (AIM: COG), which
develops and markets digital solutions to assess brain health, held
its Annual General Meeting ("AGM") earlier today at the registered
office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham,
Cambridge, CB25 9TU and announces that all resolutions put forward
were duly passed.
Proxy votes were received in respect
of approximately 55% of the Company's issued share capital and the
votes cast were as follows:
|
Resolution
|
For
|
|
Against
|
|
Withheld
|
|
1 - to approve the 2023 report and
accounts
|
22,321,648
|
99.98%
|
5,003
|
0.02%
|
642,810
|
|
2 - to appoint the
auditors
|
22,930,519
|
99.96%
|
8,503
|
0.04%
|
30,439
|
|
3 - to authorise the directors to
set the auditors remuneration
|
22,942,198
|
99.98%
|
5,003
|
0.02%
|
22,260
|
|
4 - to re-elect Richard Bungay as a
director
|
20,756,611
|
98.92%
|
226,842
|
1.08%
|
1,986,008
|
|
5 - to elect Nick Rodgers as a
director
|
22,927,961
|
99.82%
|
40,492
|
0.18%
|
1,008
|
|
6 - to elect Stuart Gall as a
director
|
22,927,961
|
99.82%
|
40,492
|
0.18%
|
1,008
|
|
7 - authority to allot
shares
|
22,798,499
|
99.26%
|
169,954
|
0.74%
|
1,008
|
|
8 - disapplication of pre-emption
rights
|
22,789,981
|
99.22%
|
178,472
|
0.78%
|
1,008
|
|
9 - disapplication of pre-emption
rights in connection with an acquisition or specified capital
investment
|
22,788,299
|
99.22%
|
180,154
|
0.78%
|
1,008
|
Change of Name of Nominated Adviser and
Broker
The Company also announces that its
Nominated Adviser and Joint Broker has changed its name to Panmure
Liberum Limited following completion of its own corporate
merger.
Enquiries
|
Cambridge Cognition Holdings plc
|
|
Matthew Stork, Chief Executive
Officer
|
|
Stephen Symonds, Chief Financial
Officer
|
|
www.cambridgecognition.com
Tel: 01223
810 700
|
|
Panmure Liberum Limited (NOMAD & Joint
Broker)
|
|
Freddy Crossley / Emma Earl / Mark
Rogers
|
|
Rupert Dearden
|
|
Tel: 020
78862500
(Corporate
Advisory)
(Corporate
Broking)
|
|
|
|
Dowgate Capital Limited (Joint Broker)
|
|
David Poutney / James
Serjeant
|
|
Tel: 020
3903 7715
(Corporate
Broking)
|
|
Hudson Sandler (Financial PR
and IR)
Dan de Belder / Hattie
Dreyfus
|
Tel: 020
7796 4133
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology
company marketing digital health products to better understand,
detect and treat conditions affecting brain health. The Company's
software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients
early and improve global efficiency in pharmaceutical and
healthcare industries.
For further information visit
www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGDZGZVZRNGDZM
Cambridge Cognition (LSE:COG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
